COPD – AfricaNewsAnalysis

Novartis data presented at ERS showcases once-daily COPD portfolio and further demonstrates efficacy of Ultibro® Breezhaler® (QVA149)

08/09/2013 ANA 0

Novartis announced today new analyses of data for once-daily Ultibro® Breezhaler® (investigational QVA149 – indacaterol 85 mcg/glycopyrronium 43 mcg delivered dose, equivalent to 110 mcg/50 mcg metered dose per capsule), which showed significant improvements in […]

Novartis showcases 39 abstracts highlighting robust respiratory portfolio at ERS 2013

05/09/2013 ANA 0

New data to be presented from the Novartis respiratory portfolio at the European Respiratory Society (ERS) Annual Congress 2013 in Barcelona, Spain, further demonstrates Novartis’ commitment to providing treatment options for patients with chronic obstructive […]

Novartis first in class once-daily dual bronchodilator Ultibro® Breezhaler® (QVA149) gains positive CHMP opinion for the treatment of COPD

26/07/2013 ANA 0

Novartis announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for approval of once-daily Ultibro® Breezhaler® (indacaterol 85 mcg/glycopyrronium 43 mcg delivered dose, equivalent […]